{"entity":{"id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","aka":[],"tldr":"A phase 2 trial of pCAR-19B cells in acute lymphoblastic leukaemia and childhood cancers, run by Chongqing Precision Biotech Co., Ltd, now recruiting.","summary":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents is a phase 2 interventional study registered as NCT05334823 by Chongqing Precision Biotech Co., Ltd, with 100 participants planned, started 2022-01-26 and due to reach its primary completion in 2028-12-31. Interventions recorded: pCAR-19B cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05334823","url":"https://clinicaltrials.gov/study/NCT05334823"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["chongqing-precision-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05334823","phase":"2","setting":"A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL","sponsor":"Chongqing Precision Biotech Co., Ltd","enrolled":100,"outcomes":[]},"route":"/trials/nct05334823/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/"}]}}